We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > urothelial cancer

News List

Deals this week: AstraZeneca, Yuhan, Bristol-Myers americanpharmaceuticalreviewpharmaceutical-technol
November 10, 2018
Covis Pharma currently markets the drugs in the US. The divestment will enable AstraZeneca to focus on the development of new and innovative drugs to fulfil the unmet needs of patients.
NICE rejects Roche’s Tecentriq for pre-treated urothelial cancer pharmatimes
December 25, 2017
Cost regulators for NHS treatments in England and Wales have turned down Roche’s Tecentriq for patients who have already received prior treatment for metastatic urothelial cancer.
Priority review for Merck, Pfizer’s avelumab in urothelial cancer pharmatimes
March 02, 2017
US regulators have agreed to undertake a priority review Merck and Pfizer's avelumab as ...

Previous page 1 2 Next page